These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16995775)

  • 1. Update on tissue-engineered biological dressings.
    Ehrenreich M; Ruszczak Z
    Tissue Eng; 2006 Sep; 12(9):2407-24. PubMed ID: 16995775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on dermal substitutes.
    Ehrenreich M; Ruszczak Z
    Acta Dermatovenerol Croat; 2006; 14(3):172-87. PubMed ID: 17010268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A; Rogowski W
    BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Available Cellular and Tissue-Based Products for Treatment of Skin Defects.
    Liu Y; Panayi AC; Bayer LR; Orgill DP
    Adv Skin Wound Care; 2019 Jan; 32(1):19-25. PubMed ID: 30570555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study on the treatment of lower-extremity chronic venous and mixed ulcers using tissue-engineered skin substitute made by the self-assembly approach.
    Boa O; Cloutier CB; Genest H; Labbé R; Rodrigue B; Soucy J; Roy M; Arsenault F; Ospina CE; Dubé N; Rochon MH; Larouche D; Moulin VJ; Germain L; Auger FA
    Adv Skin Wound Care; 2013 Sep; 26(9):400-9. PubMed ID: 23958872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Autologous cultured skin substitutes].
    Hunziker T
    Hautarzt; 2004 Nov; 55(11):1077-84; quiz 1085. PubMed ID: 15480520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic dressings: current applications and limitations in dermatologic surgery.
    Chern PL; Baum CL; Arpey CJ
    Dermatol Surg; 2009 Jun; 35(6):891-906. PubMed ID: 19397669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers.
    Cavorsi J; Vicari F; Wirthlin DJ; Ennis W; Kirsner R; O'Connell SM; Steinberg J; Falanga V
    Wound Repair Regen; 2006; 14(2):102-9. PubMed ID: 16630097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.
    Zaulyanov L; Kirsner RS
    Clin Interv Aging; 2007; 2(1):93-8. PubMed ID: 18044080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue engineered fetal skin constructs for pediatric burns.
    Norbury WB; Jeschke MG; Herndon DN
    Crit Care; 2005; 9(6):533-4. PubMed ID: 16356232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic dressing in burns.
    Lineen E; Namias N
    J Craniofac Surg; 2008 Jul; 19(4):923-8. PubMed ID: 18650713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent.
    Trent JF; Kirsner RS
    Int J Clin Pract; 1998 Sep; 52(6):408-13. PubMed ID: 9894378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of living bilayered cell therapy (Apligraf) for heel ulcers.
    Karr J
    Adv Skin Wound Care; 2008 Jun; 21(6):270-4. PubMed ID: 18525250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Apligraf in acute wounds.
    Kirsner RS
    J Dermatol; 1998 Dec; 25(12):805-11. PubMed ID: 9990773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wound-healing protocols for diabetic foot and pressure ulcers.
    Brem H; Jacobs T; Vileikyte L; Weinberger S; Gibber M; Gill K; Tarnovskaya A; Entero H; Boulton AJ
    Surg Technol Int; 2003; 11():85-92. PubMed ID: 12931288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
    O'Meara S; Cullum N; Majid M; Sheldon T
    Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid fabricated living dermal equivalent for skin tissue engineering: an in vivo evaluation in an acute wound model.
    Ananta M; Brown RA; Mudera V
    Tissue Eng Part A; 2012 Feb; 18(3-4):353-61. PubMed ID: 21913837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers.
    Brem H; Young J; Tomic-Canic M; Isaacs C; Ehrlich HP
    Surg Technol Int; 2003; 11():23-31. PubMed ID: 12931279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue engineering for cutaneous wounds: selecting the proper time and space for growth factors, cells and the extracellular matrix.
    Macri L; Clark RA
    Skin Pharmacol Physiol; 2009; 22(2):83-93. PubMed ID: 19188756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applied tissue engineering in the closure of severe burns and chronic wounds using cultured human autologous keratinocytes in a natural fibrin matrix.
    Kopp J; Jeschke MG; Bach AD; Kneser U; Horch RE
    Cell Tissue Bank; 2004; 5(2):89-96. PubMed ID: 15241004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.